Abstract: Novel morpholino compounds having the general formula ##STR1## wherein R.sub.1 is a straight or branched alkyl group containing 8 to 16 carbon atoms at the 2- or 3-position of the morpholino ring, and R.sub.2 is a straight or branched alkyl group containing 2 to 10 carbon atoms, substituted with a hydroxy group except in the alpha-position, the sum of the carbon atoms in the groups R.sub.1 and R.sub.2 being at least 10 and preferably 10 to 20; and pharmaceutically acceptable salts thereof. Compositions for the treatment of the oral cavity and especially the tooth surfaces containing the novel compound or a salt thereof, preferably from 0.1 to 5% by weight thereof. Use of the compounds to inhibit the formation of dental plaque or remove plaque already formed by application of the compound in an aqueous solution or a composition to the surfaces of the oral cavity, especially the surfaces of the teeth. Processes for the preparation of the compounds.

Abstract: This invention relates to a method for treating human beings and animals suffering from mental disorders comprising administering to said human beings and animals an effective amount of a compound for the treatment of such mental disorders comprising a compound having the formula ##STR1## wherein R is alkyl straight or branch chained having from 1 to 10 carbon atoms, cycloalkyl having from 3 to 8 carbon atoms, aralkyl having from 7 to 9 carbon atoms or phenyl unsubstituted or substituted by one to three F, Cl, Br, lower alkyl having from 1 to 5 carbon atoms, lower alkoxy having from 1 to 5 carbon atoms, alkylenedioxy having from 1 to 3 carbon atoms, --CF.sub.3 or --CN substituents, R.sub.1 -R.sub.4 are independently H, CH.sub.3, C.sub.2 H.sub.5 with cis or trans configuration provided that only two of them are other than hydrogen, and pharmaceutically acceptable salts thereof.

Abstract: Novel morpholino compounds having the general formula ##STR1## wherein R.sub.1 is a straight or branched alkyl group containing 8 to 16 carbon atoms at the 2- or 3-position of the morpholino ring, and R.sub.2 is a straight or branched alkyl group containing 2 to 10 carbon atoms, substituted with a hydroxy group except in the alpha-position, the sum of the carbon atoms in the groups R.sub.1 and R.sub.2 being at least 10 and preferably 10 to 20; and pharmaceutically acceptable salts thereof. Compositions for the treatment of the oral cavity and especially the tooth surfaces containing the novel compound or a salt thereof, preferably from 0.1 to 5% by weight thereof. Use of the compounds to inhibit the formation of dental plaque or remove plaque already formed by application of the compound in an aqueous solution or a composition to the surfaces of the oral cavity, especially the surfaces of the teeth. Processes for the preparation of the compounds.

Abstract: A sustained-release coated pharmaceutical tablet comprising a drug-containing tablet and a coating or membrane surrounding the same, wherein the coating or membrane is water-insoluble and insoluble in gastrointestinal fluids and consists essentially of a terpolymer of polyvinylchloride, polyvinylacetate, and polyvinylalcohol and a water-soluble pore-creating substance, the said pore-creating substance being randomly distributed in said terpolymer coating, said pore-creating substance being present in amount of one part to 35 parts for each one to ten parts of terpolymer, said coated tablet exhibiting a substantially constant dissolution rate during a major portion of its dissolution time when exposed to gastrointestinal fluids, especially wherein the terpolymer contains 80 to 95% weight per weight of polyvinylchloride, 0.5 to 19% weight per weight of polyvinylacetate, and 0.5 to 10% weight of polyvinylalcohol, and a method for the preparation thereof, are disclosed.

Abstract: A sustained-release coated pharmaceutical tablet comprising a drug-containing tablet and a coating or membrane surrounding the same, wherein the coating or membrane is water-insoluble and insoluble in gastrointestinal fluids and consists essentially of a terpolymer of polyvinylchloride, polyvinylacetate, and polyvinylalcohol and a water-soluble pore-creating substance, the said pore-creating substance being randomly distributed in said terpolymer coating, said pore-creating substance being present in amount of one part to 35 parts for each one to ten parts of terpolymer, said coated tablet exhibiting a substantially constant dissolution rate during a major portion of its dissolution time when exposed to gastrointestinal fluids, especially wherein the terpolymer contains 80 to 95% weight per weight of polyvinylchloride, 0.5 to 19% weight per weight of polyvinylacetate, and 0.5 to 10% weight of polyvinylalcohol, and a method for the preparation thereof, are disclosed.

Abstract: A sustained-release coated pharmaceutical tablet comprising a drug-containing tablet and a coating or membrane surrounding the same, wherein the coating or membrane is water-insoluble and insoluble in gastrointestinal fluids and consists essentially of a terpolymer of polyvinylchloride, polyvinylacetate, and polyvinylalcohol and a water-soluble pore-creating substance, the said pore-creating substance being randomly distributed in said terpolymer coating, said pore-creating substance being present in amount of one part to 35 parts for each one to ten parts of terpolymer, said coated tablet exhibiting a substantially constant dissolution rate during a major portion of its dissolution time when exposed to gastrointestinal fluids, especially wherein the terpolymer contains 80 to 95% weight per weight of polyvinylchloride, 0.5 to 19% weight per weight of polyvinylacetate, and 0.5 to 10% weight of polyvinylalcohol, and a method for the preparation thereof, are disclosed.

Abstract: Compounds having the general formula ##STR1## as herein defined and pharmaceutically acceptable acid addition salts thereof. Pharmaceutical compositions containing said compounds. Methods of treatment of humans and animals by such compounds and compositions.

Abstract: Compounds having the general formula ##STR1## as herein defined and pharmaceutically acceptable acid addition salts thereof. Pharmaceutical compositions containing said compounds. Methods of treatment of humans and animals by such compounds and compositions.

Abstract: Aryl ethers of N-alkyl-piperdines having the formula ##STR1## wherein R.sub.1 represents hydrogen, halogen including F, Cl and Br, a lower alkanoyl group (e.g. alkanoyl of up to five carbon atoms), an alkenyl group (having three to five carbon atoms) or phenoxy, R.sub.2 represents hydrogen, halogen including F, Cl and Br, --CN group, a lower alkoxy group (e.g. alkoxy of up to five carbon atoms), a lower alkanoyl group (e.g. alkanoyl of up to five carbon atoms), an alkenyloxy or alkynyloxy group (having three to five carbon atoms) or a lower alkoxycarbonyl group (e.g. alkoxycarbonyl of up to five carbon atoms), R.sub.3 and R.sub.4 independently represent hydrogen, halogen including F, Cl and Br, a --CF.sub.3 group, a lower alkyl group (e.g. alkyl of up to five carbon atoms) or a lower alkoxy group (e.g. alkoxy of up to five carbon atoms), R.sub.5 represents hydrogen or an acyl group with 2-19 carbon atoms and n=3 or 4, and pharmaceutically acceptable acid addition salts.

Abstract: A method of treating diarrhoea and promoting weight gain in mammals by administration of an effective amount of a compound selected from the group consisting of 4-fluoro-.gamma.-(4-alkylpiperidino)-butyrophenone of the formula ##STR1## wherein R is lower alkyl having 1 to 6 carbon atoms, or pharmaceutically acceptable acid addition salts thereof.

Abstract: Compounds having the general formula ##STR1## as herein defined and pharmaceutically acceptable acid addition salts thereof. Pharmaceutical compositions containing said compounds. Methods of treatment of humans and animals by such compounds and compositions.

Abstract: 2,3,4,7,8,9-Substituted octahydropyrazinopyrimidinones and acid addition salts thereof. A process for the preparation of said compounds. A pharmaceutical composition comprising such a compound and a conventional carrier. A process for the preparation of said composition. Method of medical treatment of human beings and animals using such compounds.

Abstract: Aminoalcohol compounds and acid addition salts thereof, useful in the prevention and treatment of dental caries and periodontitis, are disclosed. Methods of preparing said derivatives, orally acceptable compositions containing said compounds, and a method of treatment therewith are also disclosed.

Abstract: Novel spiro 1-(hydroxyalkyl)-piperidino derivatives and acid addition salts thereof, useful in the prevention and treatment of dental caries and periodontitis, are disclosed. Methods of preparing said derivatives, orally acceptable compositions containing said compounds, and a method of treatment therewith are also disclosed.

Abstract: Novel gamma-(4-lower-alkyl-4-lower-alkoxypiperidino)-p-fluorobutyrophenones and acid addition salts thereof, useful as central depressants, e.g., neuroleptics (antipsychotics). Pharmaceutical compositions thereof and method of treating therewith.

Abstract: Novel 4,4-diphenylbutyl-1-(4-benzoyl-4-hydroxy or acyloxy)-piperidines and acid addition salts thereof, useful as central depressants, e.g., neuroleptics (anti-psychotics), are disclosed. Methods of making same, pharmaceutical compositions thereof, a method of treating therewith, and important and novel intermediates for the production thereof, namely, 4-benzoyl-4-hydroxypiperidines, are also disclosed, as well as 4-benzoyl-1-(4,4-diphenylbutyl)-piperidines, which are also useful intermediates.

Abstract: Novel 1-substituted-4-aroyl-4-hydroxy and -4-acyloxypiperidines and acid addition salts thereof, useful as central nervous system depressants and neuroleptics with pronounced antipsychotic effects, are disclosed. Methods of making same, pharmaceutical compositions thereof, a method of treating therewith, and important and novel intermediates for the production thereof, are also disclosed.